Search results
Results From The WOW.Com Content Network
This may result in side effects such as fluid retention and gynecomastia. [3] Like other AAS, nandrolone decanoate has antigonadotropic effects. [3] It has been found to suppress testosterone levels by 57% at a dosage of 100 mg/week and by 70% at a dosage of 300 mg/week in men following 6 weeks of treatment. [3]
Decabromodiphenyl ether (also referred to as decaBDE, DBDE, BDE-209) is a brominated flame retardant which belongs to the group of polybrominated diphenyl ethers (PBDEs). It was commercialised in the 1970s and was initially thought to be safe, [3] [4] but is now recognised as a hazardous and persistent pollutant.
It is also an anabolic steroid (AAS) which is medically used in the form of esters such as nandrolone decanoate (brand name Deca-Durabolin) and nandrolone phenylpropionate (brand name Durabolin). [ 2 ] [ 12 ] [ 8 ] [ 13 ] Nandrolone esters are used in the treatment of anemias , cachexia ( muscle wasting syndrome), osteoporosis , breast cancer ...
The idea behind an annual scan is that by gathering a data set every 365 days (or thereabouts), Neko’s team will be able to track and observe fluctuations in your health and advise you on what ...
Testosterone decanoate (BAN Tooltip British Approved Name) is an androgen and anabolic steroid and a testosterone ester. [1] [2] [3] [4] It is a component of Sustanon ...
Clinical data; Pronunciation / t ɛ ˈ s t ɒ s t ə r oʊ n ə n ˈ d ɛ k ə n oʊ eɪ t / teh-STOS-tə-rohn ən-DEK-ə-noh-ayt : Trade names: Oral: Kyzatrex, Andriol, Jatenzo, Testoheal, others IM: Aveed, Nebido, others: Other names: TU; Testosterone undecylate; Testosterone 17β-undecanoate; ORG-538; CLR-610: AHFS/Drugs.com: Monograph ...
Testosterone cypionate is converted by the body to testosterone that has both androgenic effects and anabolic effects; [4] still, the relative potency of these effects can depend on various factors and is a topic of ongoing research.
Side effects of vosilasarm in preliminary clinical studies in women with metastatic breast cancer have included vomiting (27%), dehydration (27%), constipation, decreased appetite and weight loss (27%), hypophosphatemia, decreased sex hormone-binding globulin (SHBG) levels (100%), increased prostate-specific antigen (PSA) levels (80%), and abnormal liver function tests, including elevated ...